MEDS - Trxade Group, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.30
-0.17 (-2.63%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close6.47
Open6.50
Bid6.14 x 1400
Ask6.35 x 900
Day's Range6.12 - 6.50
52 Week Range0.85 - 11.60
Volume13,221
Avg. Volume56,990
Market Cap48.525M
Beta (5Y Monthly)-1.74
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMay 04, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.75
  • GlobeNewswire

    Trxade Group Announces Addition to the Russell MicroCap Index

    Trxade Group, Inc. (MEDS) an integrated drug procurement, delivery and healthcare platform, announced that it has been selected to be added to the Russell MicroCap Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the U.S. market opens on June 29, 2020, according to a preliminary list of additions posted June 5, 2020. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

  • ACCESSWIRE

    Trxade Group to Deliver Virtual Presentation on June 24th, 2020 at 11:30 a.m. Eastern time

    TAMPA, FL / ACCESSWIRE / June 15, 2020 / Trxade Group, Inc. (MEDS) an integrated drug procurement, delivery and healthcare platform, announced today that management will deliver a virtual presentation on Wednesday, June 24, 2020 at 11:30 a.m. Eastern time. Suren Ajjarapu, Chief Executive Officer of Trxade Group, Inc., will present an overview of the business model and growth initiatives of the company. The webinar will be accompanied by a presentation and followed by a question and answer session, which can be accessed via the webcast link or dial-in numbers below.

  • GlobeNewswire

    Taglich Brothers Initiates Coverage of Trxade Group, Inc.

    Trxade Group Inc., headquartered in Tampa, Florida, is an integrated technology and services company focused on delivering an effective process for purchasing and delivering prescription drugs to independent pharmacies and consumers in the US. The company is developing the ability to provide healthcare services to patients without the patient leaving their home. The Company defines the microcap segment of the equity market as companies with less than $250 million in market capitalization.

  • GlobeNewswire

    Trxade Group Appoints Senior Healthcare Executive Ashton Maaraba as President of Bonum Health

    Trxade Group, Inc. (MEDS) an integrated drug procurement, delivery and healthcare platform, announced today that Ashton Maaraba is joining the Company as President of Bonum Health, Trxade Group’s telemedicine practice. Maaraba joins Trxade Group with over 20 years of experience in developing and directing strategic national sales, marketing, and operating initiatives in ever-changing, dynamic environments. Maaraba was previously the Senior Vice President of Change Healthcare/eRx Network Inc., one of the largest, independent healthcare technology companies providing software and analytics, connectivity, communications, payments, consumer engagement and workflow optimization solutions.

  • ACCESSWIRE

    47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th

    NEW YORK, NY / ACCESSWIRE / June 3, 2020 / The Virtual Summer Summit will take place on June 9 th -12 th , connecting 47 presenting small and microcap companies with distinguished investors from around ...

  • ACCESSWIRE

    Trxade Group to Present at the June 2020 Virtual Investor Summit

    TAMPA, FL / ACCESSWIRE / June 3, 2020 / Trxade Group, Inc. (NASDAQ: MEDS ), an integrated drug procurement, delivery and healthcare platform, today announced that management will present at the June 2020 ...

  • Does Trxade Group, Inc.'s (NASDAQ:MEDS) CEO Pay Matter?
    Simply Wall St.

    Does Trxade Group, Inc.'s (NASDAQ:MEDS) CEO Pay Matter?

    Suren Ajjarapu became the CEO of Trxade Group, Inc. (NASDAQ:MEDS) in 2014. First, this article will compare CEO...

  • GlobeNewswire

    Trxade Group, Inc. Withdraws Its Previously Filed FDA Emergency Use Authorization for Rapid COVID-19 Testing Kit in Response To FDA Guidance

    Trxade Group, Inc. (NASDAQ: MEDS), an integrated drug procurement, delivery and healthcare platform, announced today that its wholly-owned subsidiary, Integra Pharma Solutions, LLC, has formally withdrawn its Emergency Use Authorization (EUA) application in connection with its partner’s manufacture of the SARS-CoV-2 IgM/IgG Antibody Rapid Test Kit from consideration in response to U.S. Food and Drug Administration (FDA) guidance. The decision to withdraw the EUA application was made after much discussion with its partnered manufacturer. Per FDA guidance, only one EUA application is allowed per manufactured kit product.

  • GlobeNewswire

    TRxADE Group Reports First Quarter 2020 Financial Results

    Q1 2020 Revenues Increase 46% to $2.2 Million; Drives Net Income Increase of 44% to $0.2 Million TAMPA, FL, May 04, 2020 -- Trxade Group, Inc., (NASDAQ: MEDS) (“Trxade” or.

  • GlobeNewswire

    Trxade Group Inc. Featured in Broadcast on Companies Aiding Coronavirus Front Lines

    New York, April 30, 2020 -- Trxade Group Inc. Featured in Broadcast on Companies Aiding Coronavirus Front Lines NEW YORK (April 30, 2019) – via NetworkNewsAudio –Trxade.

  • GlobeNewswire

    Trxade Group Inc. Featured in Editorial on Medical Supply Companies’ Critical Role in Coronavirus Battle

    New York, April 29, 2020 -- via NetworkWire — Trxade Group Inc. (NASDAQ: MEDS) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 40+.

  • ACCESSWIRE

    Trxade Group Engages MZ Group to Lead Investor Relations and Shareholder Communication Program

    TAMPA, FL / ACCESSWIRE / April 28, 2020 / Trxade Group, Inc. (MEDS) an integrated drug procurement, delivery and healthcare platform, has engaged international investor relations specialists MZ Group (MZ) to expand its comprehensive strategic investor relations and financial communications program across all key markets. MZ Group will work closely with Trxade Group management to develop and implement a comprehensive capital markets strategy designed to increase the Company's visibility throughout the investment community. The comprehensive investor relations campaign will highlight the Company's record 2019 financial results - validating its proprietary trading platform model, as well as the recent launch of its drug delivery and Telehealth platforms, each addressing significant new markets.

  • ACCESSWIRE

    Trxade Group, Inc signed up its First Employer to Supply COVID-19 Testing Kits

    TAMPA, FL / ACCESSWIRE / April 27, 2020 / Trxade Group, Inc. (NASDAQ: MEDS ) (hereinafter "Trxade") an integrated drug procurement, delivery and healthcare platform signs first Covid-19 antibody ...

  • GlobeNewswire

    Trxade Featured in Broadcast on Much-Needed Solutions to Healthcare Dilemma

    NEW YORK, April 03, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Trxade Group Inc. (MEDS) announces the availability of a broadcast titled, “US Faces Biggest Healthcare Challenge — It’s not COVID-19.” America offers some of the most advanced health services in the world, but access and affordability remain out of reach for a huge swath of the population. Healthcare spending now accounts for about 18% of the nation’s GDP, soaring to $3.6 trillion ($11,172 per person) in 2018.

  • GlobeNewswire

    TRxADE GROUP, INC. Sets Date for 2020 Annual Meeting of Stockholders

    Trxade Group, Inc., (Nasdaq: MEDS)(“Trxade Group” or the “Company”), an integrated telehealth, drug procurement, delivery and healthcare platform that enables price transparency and increased profit margins to healthcare buyers and sellers of pharmaceuticals, today announced that it had scheduled its 2020 Annual Meeting of Stockholders to be held on Friday, May 29, 2020 at 10 A.M. local time at the Company’s corporate offices: 3840 Land O’ Lakes Blvd, Land O’ Lakes, Florida 34639. The record date for determination of stockholders entitled to vote at the meeting, and any adjournment thereof, is planned to be set on or around the close of business on April 13, 2020 (the “Record Date”).

  • GlobeNewswire

    Trxade Spotlighted in Publication Discussing Healthcare Challenge, Solution

    NEW YORK, April 02, 2020 -- via NetworkWire — Trxade Group Inc. (NASDAQ: MEDS) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 40+.

  • GlobeNewswire

    Trxade Group, Inc. Files FDA Emergency Use Authorization for Rapid COVID-19 Testing Kit

    Trxade Group, Inc. (NASDAQ: MEDS) an integrated drug procurement, delivery and healthcare platform, announces its wholly-owned subsidiary, Integra Pharma Solutions, has filed for an Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) in collaboration with its partnered manufacturer of the SARS-CoV-2 IgM/IgG Antibody Rapid Test Kit. Under section 564 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), the FDA Commissioner may allow unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or when there are no adequate, approved, and available alternatives. Filing the EUA has dual purposes; first it serves as notification to FDA that Trxade Group will be distributing the test and secondly, if the EUA is approved, it enables Trxade Group to market the product for diagnostic use.

  • GlobeNewswire

    TRxADE GROUP, INC. REPORTS 2019 RESULTS

    Delivered 2019 annual revenues of $7.43 Million (94.1% increase)Total Adjusted EBITDA of $852,647 (249% increase)Launched next generation of Telehealth Platform (.

  • ACCESSWIRE

    Trxade Group, Inc's Wholly Owned Subsidiary Bonum Health Offers Continuous Healthcare Coverage During Nationwide Crisis

    TAMPA, FL / ACCESSWIRE / March 26, 2020 / Trxade Group, Inc. (NASDAQ: MEDS ) an integrated drug procurement, delivery and healthcare platform has developed an affordable safety-first healthcare option ...

  • ACCESSWIRE

    Trxade Group, Inc's Wholly Owned Subsidiaries to Help Reduce Exposure to Current and Future Virus Outbreaks

    TAMPA, FL / ACCESSWIRE / March 10, 2020 / Trxade Group, Inc. (NASDAQ:MEDS) an integrated drug procurement, delivery and healthcare platform announces the onset of a new membership service by its subsidiaries ...

  • ACCESSWIRE

    Trxade Group, Inc to Exhibit at HIMSS20 Global Health Conference & Exhibition in Orlando, FL

    TAMPA, FL / ACCESSWIRE / March 5, 2020 / Trxade Group, Inc., (NASDAQ: MEDS ) ("Trxade Group or the "Company"), an integrated drug procurement, delivery and healthcare platform that enables ...

  • ACCESSWIRE

    Trxade Group to Ring Nasdaq Opening Bell on Friday, February 28, 2020

    Pharma Supply Chain Company Recently Uplisted to NASDAQ with symbol "MEDS" TAMPA, FL / ACCESSWIRE / February 26, 2020 / Trxade Group, Inc., ( NASDAQ:MEDS ) (" Trxade Group " or the ...

  • GlobeNewswire

    TRxADE GROUP, INC. Announces Exercise of Overallotment Option by Underwriters

    Trxade Group, Inc., (Nasdaq: MEDS)(“Trxade Group” or the “Company”), an integrated drug procurement, delivery and healthcare platform that enables price transparency and increased profit margins to healthcare buyers and sellers of pharmaceuticals, today announced the exercise by the underwriters of the Company’s previously announced firm commitment underwritten offering which closed on February 18, 2020, of their overallotment option and the purchase by such underwriters of 115,767 shares of common stock at the public offering price of $6.50 per share, less the underwriters’ discount of $0.52 per share, resulting in net pricing of $5.98 per share. Trxade Group received gross proceeds of approximately $0.7 million from the sale of common stock from the underwriters’ exercise of their overallotment option, prior to deducting offering expenses.

  • GlobeNewswire

    TRxADE GROUP, INC. Announces Closing of Firm Commitment Common Stock Offering

    Trxade Group, Inc., (Nasdaq: MEDS)(“Trxade Group” or the “Company”), an integrated drug procurement, delivery and healthcare platform that enables price transparency and increased profit margins to healthcare buyers and sellers of pharmaceuticals, today announced the closing of its previously announced underwritten public offering of 806,452 shares of its common stock at a price to the public of $6.50 per share. Trxade Group granted the underwriters a 45-day option to purchase up to an additional 120,967 shares of common stock in connection with the offering, to cover overallotments, if any. Trxade Group received gross proceeds of $5.24 million from the sale of common stock in the offering, prior to deducting the underwriting discounts and offering expenses.